On air · 2 of 3 networks
Genovis
- genovis.com
- Healthcare & Life Sciences
- SE
- 52 employees
Genovis’s ads on LinkedIn, Meta and Google, recorded by adsrunning. Browse the latest here for free. Sign up free to see all 40. Watch Genovis with Starter to get each new one in your feed.
Watchlist with Starter · $49/mo
| Network | Status | Live ads | Nov 2025LinkedIn activity · 52 weeksOct 2026 | Checked | Next step |
|---|---|---|---|---|---|
| Running | 16 | Checked 31 Oct 2026 | See all 40 ads → | ||
| Meta | Not checked | — | |||
| Running | 3 | Ads on the Google Ads Transparency Center | Checked 30 Oct 2026 | Collect them with the API → |
Genovis has 16 live LinkedIn ads. We recorded 3 Google ads on 30 Oct 2026.
Latest ads
- LINKEDIN · IMAGESince 28 Oct 2026
Join Benqian Wei from Merck for our next GenovisWebinar: Advancing Biotherapeutic Characterization – HILIC-MS-Enabled Subunit-Level MAM. Benqian will show how FabRICATOR® subunit digestion combined with HILIC-MS improves separation and monitoring of critical PQAs in complex biotherapeutics – with case studies on IgG and Fc-fusion proteins. Relevant for analytical scientists, MS-based MAM in R&D and QC, CROs, and lab heads optimizing PQA monitoring. 📅 Thursday Nov 12 | 10 AM ET / 4 PM CET
- LINKEDIN · IMAGESince 28 Oct 2026
Peptide-based MAM gives you detail – but at the cost of long sample preparation and LC-MS run times. On November 12, Benqian Wei from Merck shows how a HILIC-MS-based subunit-level MAM with FabRICATOR® lets you monitor multiple product quality attributes in a single assay – faster, with reproducible quantitative performance. You'll see: • Improved chromatographic separation of PTMs • N- and O-glycosylation, deamidation, oxidation and succinimide formation at the subunit level • Case studies on IgG and Fc-fusion proteins 📅 Thursday Nov 12 | 10 AM ET / 4 PM CET
- LINKEDIN · IMAGESince 25 Sept 2026
Now from Genovis: TrypsINATOR™ + LysCERATOR™ in One Reagent LysCERATOR just got a "partner-in-digest" 🤩 The TrypsINATOR LysCERATOR Mix combines TrypsINATOR and LysCERATOR in a single reagent — Genovis's own take on dual-specificity digestion, built for even cleaner peptide pools from complex samples. And with minimal autoproteolysis, you get the added coverage without the background noise trypsin is known for! The result: up to 88% fully cleaved peptides in human cell lysates. Discover the TrypsINATOR LysCERATOR Mix 👉
- LINKEDIN · IMAGESince 16 Aug 2026
Still struggling with missed cleavages at K–P sites? Let’s see how LysCERATOR™ stacks up against traditional Lys-C enzymes In head-to-head trastuzumab experiments, LysCERATOR™ outperformed standard Lys-C at challenging lysine–proline (K–P) sites. In what ways? • Higher Efficiency: Superior digestion at K–P sites. • Cleaner Results: Significantly fewer missed cleavages. • Better Mapping: Improved sequence coverage and reliability. Check out the trastuzumab K–P digestion data here 👉
- LINKEDIN · IMAGESince 14 Aug 2026
How much are missed cleavages affecting your data? 🤔 LysCERATOR™ is designed to deliver high digestion efficiency and strong lysine specificity—helping you generate more informative peptide pools from complex samples. In HeLa lysates, it produced more unique peptides and a higher proportion of fully cleaved peptides compared to alternative Lys-C enzymes. Discover how LysCERATOR works on HeLa Cell Lysates 👉
- LINKEDIN · IMAGESince 11 Jun 2026
Fresh from ASMS: New LysCERATORTM data is now available! 🌟🦈 Our latest poster highlights the versatility of LysCERATOR™ across a broad range of digestion conditions. Among the findings: efficient digestion under mildly acidic conditions (pH 5–6), supporting disulfide mapping workflows where preserving native disulfide linkages is important. 📄 Download the ASMS poster and explore the results for yourself! Find your LysCERATOR application here: https://lnkd.in/emKDiiPi
6 of 40 adsSign up to see every Genovis ad, filter by format and date, and get alerts on new ones.
See all 40 adsWatch the companies you care about.
Filter every ad by industry, country, format and network, and get alerts when a company you watch starts running new ads.